{"id":11361,"date":"2024-08-14T10:32:12","date_gmt":"2024-08-14T10:32:12","guid":{"rendered":"https:\/\/www.friendly-bartik.94-130-216-58.plesk.page\/noah\/"},"modified":"2026-05-11T12:25:30","modified_gmt":"2026-05-11T12:25:30","slug":"noah","status":"publish","type":"page","link":"https:\/\/www.af-net.eu\/en\/noah\/","title":{"rendered":"NOAH"},"content":{"rendered":"\n
\n
\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

NOAH<\/strong>-AFNET 6<\/h2>\n\n\n\n
<\/div>\n\n\n\n

N<\/strong>on-vitamin K antagonist O<\/strong>ral anticoagulants in patients with A<\/strong>trial H<\/strong>igh-rate episodes<\/p>\n<\/div>\n<\/div>\n<\/div><\/div>\n\n\n\n

<\/div>\n\n\n\n
\n
\n
\n

study design<\/strong><\/h2>\n\n\n\n
<\/div>\n\n\n\n

Investigator-driven, prospective, parallel-group, randomized, event-driven, double-blind, multicenter phase IIIb trial to evaluate the potential benefit of oral anticoagulation therapy in patients with AHRE, but without overt AF. The trial is to test whether treatment with the newly introduced NOAC edoxaban is superior to current therapy to prevent stroke, systemic embolism, or cardiovascular death in this patient group.<\/p>\n<\/div>\n\n\n\n

\n
\"\"<\/figure>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
Inclusion criteria<\/strong><\/h5>\n\n\n\n

\"\" Pacemaker or defibrillator implanted for any reason with feature of detection of AHRE, implanted at least 2 months prior to randomization<\/p>\n\n\n\n

\"\" AHRE (\u2265 180 bpm atrial rate and \u2265 6 min duration) documented by the implanted device via its atrial lead and stored digitally<\/p>\n\n\n\n

\"\" Age \u2265 65 years<\/p>\n\n\n\n

\"\" In addition, at least one stroke risk factor leading to a CHA DS VASc score of 2 or more.<\/p>\n<\/div>\n\n\n\n

\n
Exclusion criteria<\/strong><\/h5>\n\n\n\n

\"\" Any disease that limits life expectancy to less than 1 year<\/p>\n\n\n\n

\"\" Participation in another controlled clinical trial, either within the past two months or still ongoing<\/p>\n\n\n\n

\"\" Previous participation in the present trial NOAH – AFNET 6<\/p>\n\n\n\n

\"\" Drug abuse or clinically manifest alcohol abuse<\/p>\n\n\n\n

\"\" Any history of overt AF or atrial flutter<\/p>\n\n\n\n